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Abstract
Background: The importance of the standardisation of 
immunoassays for autoantibodies has been widely dis-
cussed. The appropriate use of certified reference materi-
als (CRM) could contribute to a more accurate diagnosis 
and follow-up of a series of diseases such as small vessel-
associated vasculitis. This is a systemic autoimmune disor-
der during which two autoantibodies can be present, MPO 
ANCA IgG and PR3 ANCA IgG. Results from different com-
mercially available immunoassays used for PR3 ANCA IgG 
measurement can vary significantly. Therefore the potential 
for improvement using a suitable certified reference mate-
rial was assessed and led to the development of a CRM.
Methods: Thirty clinical samples were evaluated using 
10 immunoassays. The correlation between results from 
these assays was assessed in a pairwise manner. Feasibility 
studies were conducted in order to find a reference material 
format most suitable for the preparation of a CRM.
Results: The evaluation of two sets of 30 clinical samples 
with 10 assays showed that differences between assays 
can result in different interpretations for individual clini-
cal samples. Most of the samples had the same result clas-
sification in all assays. However, six of the samples tested 
led to inconsistent results.
Conclusions: The correlation between results from clini-
cal samples was systematically good for combinations of 
eight of those assays. Therefore, it should be possible to 
improve the comparability of results using a commutable 
CRM for calibration. Based on these studies, a final format 
for the CRM was selected and eventually produced and 
certified for its PR3 ANCA IgG content.
Keywords: autoimmune disease; commutability; immu-
noassay; in vitro diagnostics; PR3 ANCA; reference mate-
rial; standardisation.
Introduction
PR3 and disease
Anti-neutrophil cytoplasmic antibodies (ANCAs) were 
described as crucial diagnostic markers for small-vessel 
vasculitis already in 1985 [1]. There are two main targets for 
the antibodies responsible for most of the sub-categories 
of small-vessel vasculitis. Antibodies against myeloperoxi-
dase (MPO) are detected mostly in microscopic polyangiitis 
(MPA) and eosinophilic granulomatosis with polyangiitis 
(EGPA), and against proteinase 3 (PR3) in granulomatosis 
with polyangiitis (GPA) [2]. Interestingly, there seems to be 
a geographical pattern in the appearance of all the types, 
with PR3 ANCA being mostly encountered in Northern 
Europe and southern New Zealand, while MPO ANCA is 
more often encoutered in Mediterranean countries. In addi-
tion to the geographical pattern, PR3 ANCA seems to be 
more prevalent in Caucasians than in Asians or Africans [3].
PR3 measurements
According to the Chapel Hill Consensus of 2012, the labo-
ratory investigation includes a screening test by indirect 
immunofluorescence (IIF), which can be followed by con-
firmation with specific enzyme-linked immunosorbent 
assays (ELISAs) for IgG antibodies to PR3 and/or MPO [4]. 
Recently, a group of international experts proposed a revi-
sion of the consensus, where the value of immunoassay 
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testing for diagnosis is highlighted. Modern immuno-
assays have improved performance especially over the 
more traditional IIF [5]. PR3 ANCA IgG antibodies present 
a wide variation in the concentration values generated 
for the same sample by different commercially available 
immunoassays. Part of the reason is that companies use 
arbitrary units, often different ones, making it impossible 
to compare results between the various available assays.
PR3 CRM
In 2010, the International Federation of Clinical Chem-
istry and Laboratory Medicine (IFCC) formed a working 
group to collaborate with the Joint Research Centre of 
the European Commission on the harmonisation of auto-
immune antibody testing. The first objective of this group 
was to establish whether it is possible to develop refer-
ence systems including CRMs that have property values 
metrologically traceable to the International System of 
Units (SI) for selected autoantibody tests. The ultimate 
aim was to prepare CRMs that would be widely avail-
able for standardisation of serology testing of several 
autoantibodies, amongst them, a CRM for PR3 ANCA IgG 
antibodies.
The development of a CRM for PR3 ANCA IgG was the 
logical continuation after the successful development and 
release of ERM-DA476/IFCC, a CRM for MPO ANCA IgG. A 
reference material has to resemble a clinical sample so as 
to minimise calibration bias and be of value [6–9]. This 
property of a CRM is known as commutability. It can be 
simply defined as the property of a reference material (RM) 
to mimic the characteristics of a typical clinical sample in 
two or more measurement procedures for a stated measur-
and [10]. Two commutability studies were performed in a 
period of 3 years, comparing the results for a representative 
number of clinical samples and candidate reference materi-
als across various assays. In the first study the comparability 
of results from a selected number of assays was assessed, 
and different raw materials and CRM formats were evalu-
ated. A second study was performed in order to further vali-
date the most promising candidate CRMs, using a smaller 
selection of assays. The measurements for the second study 
were performed using a different set of clinical samples.
Comparability of results from different 
assays
There are a number of factors contributing to the variability 
of autoantibody results. Monogioudi et al. summarised them 
in a recent paper [11]. These factors include a wide selection 
from the principles of in vitro diagnostic (IVD) assays, the 
repeatability and intermediate precision of each one of them, 
the different scales and units used from the manufacturers 
but also the sample-specific variation, mainly due to the spe-
cific antigen used for the development of an assay.
For our studies, from their initial steps of the feasibil-
ity and commutability to eventually the development of the 
CRM and its characterisation, most of these factors were 
taken into account and eventually only the sample spe-
cific variation and the different scales used by the different 
assays were left to account for any differences observed.
In this paper we are mainly presenting the results 
of the preliminary correlation studies for PR3 ANCA IgG 
assays, report the results in analytical terms, describe 
how the CRM was prepared and briefly discuss the char-
acterisation process of this material. Further details and 
information can be found on the certification report of the 
material, ERM-DA483/IFCC [12].
Materials and methods
Serum samples
Clinical samples were collected based on the amounts available and 
their PR3 ANCA IgG concentration. Two separate commutability assess-
ments were performed and in total 60 serum samples were used (30 in 
the first and 30 in the second study). Serum samples were from patients 
undergoing PR3 ANCA IgG testing at the Protein Reference Unit and 
Immunopathology Department, St. Georges’ Hospital (London, GB). 
Each sample was anonymised following national ethical laws.
Candidate reference materials processing
The raw materials used were three plasmapheresis materials from 
patients with high concentrations of PR3 ANCA IgG. The materials 
were collected at the Staten Serum Institute, (Copenhagen, DK) and 
coded as SSIA, SSIC and SSIG. Table 1 summarises the different can-
didate reference materials that were produced on the basis of these 
three materials. They include plasma serum based on the three raw 
materials, and processed serum from SSIA, and purified PR3 IgG 
ANCA spiked into processed or unprocessed serum from healthy 
donors, all types of materials both liquid frozen and freeze-dried. 
The processing of the material chosen to prepare the CRM from is 
described in detail elsewhere [12].
Commutability studies
Commutability studies were performed prior to the decision on the 
final format of the reference material and the production of the CRM. 
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These studies are important so as to establish the conditions under 
which a CRM should be prepared in order to behave like a fresh 
patient sample in the various commercial assays.
Performance of the commutability studies: In the first commutabil-
ity study 18 different formats of candidate RMs were tested (Table 1). 
These samples were analysed with eight ELISAs, which are mostly 
used in UK-NEQAS studies (Table 2). The formats of the candidate 
RMs tested varied from plasma samples, to serum and to purified 
PR3 ANCA IgG spiked into them. All ELISA measurements were per-
formed on three plates per assay. On each of the three plates 21 of 
the clinical samples were measured in duplicate. The nine remaining 
clinical samples and the candidate RM samples were measured in 
duplicate in two of the three plates.
In the second commutability study, three liquid frozen candi-
date RMs were analysed (Table 1). It was decided to analyse them 
and dilutions thereof, in order to ensure that the RM concentrations 
were in the measurement interval of the assays. Those samples 
together with 30 clinical samples were measured in triplicate on 
two ELISA plates. Samples taken from different aliquots were also 
measured in triplicates with an automated Phadia 250 platform. For 
both studies all reconstitution and dilution volumes were gravimet-
rically controlled and the dilution levels were calculated from the 
masses and the densities rather than from the intended volumes. 
All measurements were performed at St. Georges’ Hospital (Lon-
don, UK).
Data analysis: Commutability was assessed by comparing the 
results for candidate reference materials with the results obtained 
for clinical samples (Analyse-it Software, Leeds, UK). For each sam-
ple the average values per plate were calculated and used for the 
analysis. First Pearson’s correlation coefficient was calculated for the 
results of the clinical samples for all pairs of assays. For the pairs 
with a correlation coefficient higher than 0.75 a linear regression was 
applied and the 95% prediction interval calculated. A candidate ref-
erence material or dilution thereof was considered commutable when 
its results were within the 95% prediction interval of this regression 
performed on the results from clinical samples.
Characterisation of the certified reference material  
ERM-DA483/IFCC
Homogeneity and stability of the CRM: For the assessment of the 
between-unit homogeneity of the final material a number of vials are 
selected corresponding approximately to the cubic root of the total 
number of vials produced. These vials are selected in a random strati-
fied sampling scheme covering the whole batch. Triplicates were 
measured on the same day with a chemiluminescent immunoassay 
(QuantaFlash PR3). Regression analyses were performed to evalu-
ate potential trends both in the filling sequence and in the analytical 
sequence.
Stability studies were performed according to an isochronous 
design [13]. In this approach, units are stored for a specified length 
of time at different temperatures whereupon the units are moved to 
conditions where further degradation is assumed to be negligible. 
At the end of the isochronous storage, the samples are analysed 
Table 1: Candidate reference material formats.
First study  
 Liquid frozen  
  IRMM-PR3-1   SSIA plasma
  IRMM-PR3-2   SSIA serum
  IRMM-PR3-3   SSIA processed serum
  IRMM-PR3-4   SSIC serum
  IRMM-PR3-5   SSIG serum
  IRMM-PR3-6   Anti-PR3 IgG spiked into processed serum
  IRMM-PR3-7   Anti-PR3 IgG spiked into unprocessed 
serum from healthy donors
  IRMM-PR3-8   Anti-PR3 IgG spiked into unprocessed 
serum from healthy donors
  IRMM-PR3-9   Anti-PR3 IgG spiked into unprocessed 
serum plus additives
 Freeze dried  
  IRMM-PR3-1*  Plasma
  IRMM-PR3-2*  Serum
  IRMM-PR3-3*  Processed serum
  IRMM-PR3-4*  Serum
  IRMM-PR3-5*  SSIG serum
  IRMM-PR3-6*  Anti-PR3 IgG spiked into processed serum
  IRMM-PR3-7*  Anti-PR3 IgG spiked into unprocessed 
serum from healthy donors
  IRMM-PR3-8*  Anti-PR3 IgG spiked into unprocessed 
serum from healthy donors
  IRMM-PR3-9*  Anti-PR3 IgG spiked into unprocessed 
serum plus additives
Second study  
  Liquid frozen  
  SSIA   Processed serum
  SSIC   Processed serum
  SSIG   Processed serum
*Freeze dried samples.
Table 2: Immunoassays used in the commutability studies.
Manufacturer Assay Assay
First study
 Eurodiagnostica Wieslab Direct PR3 IU ELISA
 Eurodiagnostica Wieslab Capture PR3 ELISA
 Eurodiagnostica DIASTAT PR3 ELISA
 Euroimmun anti-PR3-hr-hn ELISA (IgG) ELISA
 Immunoconcept RELISA® PR3-ANCA TEST ELISA
 INOVA QUANTA Lite™ PR-3 IgG ELISA
 Orgentec ORG 618 Anti-PR3 (cANCA) ELISA
 Phadia Varelisa PR3 ANCA ELISA
Second study
 Phadia EliA PR3 FEIA
 Orgentec ORG 518 Anti-PR3 (cANCA) ELISA
 Eurodiagnostica DIASTAT PR3 ELISA
 Euroimmun anti-PR3-hr-hn ELISA (IgG) ELISA
PR3, proteinase 3; ELISA, enzyme linked immunosorbent assay; 
FEI, fluorescent enzyme immunoassay.
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simultaneously under repeatability conditions. The data are analysed 
by calculating the regression line for protein mass concentration in 
relation to time, and determining whether the slope is significantly 
different from zero.
Assignment of a value for PR3 IgG ANCA in ERM-DA483/IFCC: A 
calibration solution was prepared from purified PR3 IgG ANCA and 
characterised to allow the value-assignment of ERM-DA483/IFCC. A 
value for the total IgG concentration in the calibrant was assigned 
using three routine methods selective for total IgG (turbidimetry or 
nephelometry) using ERM-DA470k/IFCC as the calibrant. The con-
centration of the PR3 IgG ANCA stock solution was 0.289  mg/mL 
(2.2% uncertainty, 95% confidence interval) [12].
The value assignment of ERM-DA483/IFCC was achieved using 
a value transfer protocol that can be considered as the reference pro-
cedure [14]. It consists of use of dilutions of the IgG PR3 ANCA cali-
bration solution and routine IgG PR3 ANCA assays. The participating 
laboratories were selected based on the market share of the assays 
used, and on criteria that comprised technical competence and meet-
ing the requirements of ISO/IEC 17025 [15] or ISO 15189 [16]. Each 
participant used their own platform and reagents and was provided 
with detailed sample treatment protocols. The techniques used were 
traditional ELISAs and in some cases their variations (chemilumines-
cent and fluorescence immunoassays) specific for PR3 ANCA IgG [12]. 
A list of the assays is presented in Table 3. The samples consisted of 
vials of the CRM and eight dilutions of purified PR3 ANCA IgG pre-
pared at the facilities of JRC. The participating laboratories had to 
reconstitute the CRMs and prepare seven dilutions of each vial. Meas-
urements of all dilutions (of the reference material and the PR3 IgG 
ANCA calibration solution) were performed in triplicate in a single 
analytical run on each of 4 days.
Laboratories reported their raw data to the JRC. These data were 
assessed for their compliance with the analysis protocol and for their 
validity based on solely technical issues. No data were disregarded 
based on statistical analysis alone. Linear regressions were plotted for 
most of the assays while for some others a non-linear regression was 
observed and were treated accordingly (Table 3). Transfer factors were 
calculated for each of the datasets from the ratio of the slopes (con-
centration versus dilution) obtained for dilutions of the CRM and of 
the calibrant, as well as the concentration of the purified PR3 ANCA 
IgG [12].
Results and discussion
Commutability
Assay performance
The aim of the commutability experiments was to assess:
 – The equivalence of results from different assays. This 
includes the systematic bias (slope of the regression 
lines when results from one assay are plotted against 
the results from another assay), and sample-specific 
effects due to different selectivities of the assays (scat-
tered around the regression line)
 – The equivalence of the reference materials with rou-
tine samples
In order to focus on these issues the repeatability and 
intermediate precision were evaluated and experiments 
were designed with a sufficient number of replicates so as 
to minimise their impact. Thus, the observed scatter when 
comparing results from different assays is predominantly 
due to sample-specific effects, and not assay repeatability, 
issues with calibration, etc. As selectivity of an immuno-
assay is meant to be the ability to measure the analyte of 
interest despite the presence of other constituents [17].
The coefficient of variation (CV) of averages within and 
between plates for all samples was calculated. These calcu-
lations were performed both for the absorbance signal pro-
duced by the assays and the concentrations calculated from 
these absorbances. The results from absorbances showed 
a low intra-plate variation for all ELISAs. The inter-plate 
variation was higher, but below 7% for all assays. When the 
absorbances were converted into concentrations the CVs 
were higher. Still, between-plate CVs were below 15%.
The higher CVs for concentration values could be due 
to the fact that assays designed for the detection of PR3 
ANCA IgG include measurement intervals on the flatter 
part of the response curves, where small signal changes 
can mean large concentration changes. Additionally, not 
all assays use the same number of calibration points. Occa-
sionally the distribution of these points, especially when 
they are less than 5 is unbalanced, with fewer calibration 
points at the upper range of the measuring interval.
Immunoassay response for dilutions of clinical samples
In the second commutability study, dilutions of the chosen 
candidate CRMs were measured with four assays. Figure 1 
shows the results of clinical samples, candidate CRMs 
Table 3: List of immunoassays used in the characterisation study.
Laboratory   Assay 
number
  Assay name   Regression
L1   1  ImmuLisa™ Proteinase 3 
(PR3) antibody Enhanced
  Linear
L2   2  ORG 618 PR3 hs   Linear
L3   3  BioPlex 2200 Vasculitis   Linear
  4  Anti-PR3 EIA   Linear
L4   5  QUANTA Lite PR 3   Non-linear
  6  QUANTA Flash   Linear
L5   7  PR3 ANCA Wieslab®   Linear
L6   8  AESKULISA PR3 sensitive   Linear
L7   9  EliA PR3s   Non-linear
L8   10  Anti-PR3-hn-hr-ELISA (IgG)   Non-linear
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and dilutions thereof when analysed with an Euroimmun 
(Anti-PR3-hn-hr ELISA [IgG]) and an Orgentec kit (ORG 
518). It can be observed that patient samples, SSIC, SSIG 
and their dilutions are commutable for the combination of 
these two methods. In the case of SSIA, it seems that one 
of the dilutions is not commutable. Based on these data, 
SSIG was eventually selected for preparing the CRM.
Correlation between results from different assays
The degree of correlation of results from different assays 
was evaluated by a pairwise comparison of results from all 
assays. Pearson’s correlation coefficient (r) was calculated 
and the result interpretation was based on clinical biosta-
tistics rules [18] according to which r values ranging from 
0.75 to 1 point to a correlation which is good to excellent. 
Examples of good and bad commutability for the CRM are 
shown in Figure 2. Table 4 shows Pearson’s correlation 
coefficient for all assay comparisons of the first commut-
ability study. They varied from moderate-to-very high for 
all assays except from the couples including the Wieslab 
Capture assay, which has a different selectivity. For 14 
assay pairs the value of r was above 0.75, indicating a very 
good correlation. Moreover, five of these comparisons had 
an r value above 0.9, indicating an excellent correlation 
of the measurement results. Despite the generally good 
picture of the results, some of the clinical samples were 
outliers in some of the comparisons.
Classification and interpretation of measurement results
The results for the clinical samples were classified as posi-
tive, inconclusive or negative by using the specific cut-off 
–0.5
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
–1.0 0.0 1.0 2.0 3.0 4.0
Eu
ro
im
m
un
 (O
D)
Orgentec (OD)
Patient samples
SSIA
SSIC
SSIG
Linear (SSIG)
Figure 1: OD responses for the candidate CRMs SSIA (squares), 
SSIC (triangles) and SSIG (circles), dilutions thereof and patient 
samples (rhombus).
The values obtained in the case of SSIC are on the high end of the 
curve and above the limit of detection for the ELISAs used.
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Figure 2: Example of results for the commutability study.
Results for clinical samples are shown with a rhombus sign, results 
for SSIG as empty circles. The upper graph shows a case where the 
candidate RM is commutable. The lower graph shows an example 
where the candidate RMs is not commutable between the two 
methods compared.
CS, clinical sample; liq, liquid; proc, processed; unproc: unprocessed.
Table 4: Pearson’s correlation coefficient for the first commutability study.
    Wieslab Direct PR3 IU  Euroimmun  QUANTA Lite PR 3  ORG 618 PR3 hs  DIASTAT PR3
Varelisa PR3   0.88  0.80  0.91  0.98  0.74
Wieslab Direct PR3 IU     0.85  0.97  0.94  0.83
Euroimmun       0.86  0.89  0.79
QUANTA Lite PR 3         0.96  0.77
ORG 618 PR3 hs           0.88
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values of the different methods. In the first commutability 
study, 24 out of the 30 samples had the same classification 
among all the assays used. Nineteen samples were classi-
fied as being positive while six samples were found to be 
negative. The six remaining samples had different classi-
fications in the different assays.
Commutability of candidate reference materials
The main purpose for performing the described com-
mutability studies was to select the best material for the 
eventual development of a CRM. In the first commutabil-
ity study several different formats of the candidate RM 
were tested. As the concentrations of the undiluted plas-
mapheresis materials were rather high compared to the 
patient samples a second, smaller scale, commutability 
study was used to make the final selection of the reference 
material format.
The results from the first commutability study of the 
candidate reference materials was monitored for all of the 
28 combinations of assays for which Pearson’s correla-
tion coefficient was above 0.75. In correlation coefficients 
below 0.75, the prediction interval is very broad. This 
means that if the CRM is within this interval, it cannot be 
meaningful anymore.
Commutability can be analysed with different 
approaches as with a Passing-Bablok or Deming regres-
sion and evaluation of the results for the reference mate-
rial with respect to the 95% prediction interval.
Overall, the commutability of the material SSIG, 
including its dilutions, is good. In Figure 3 pairwise com-
parisons of the clinical samples and the CRM are shown. 
This CRM is processed as the material ERM-DA470k/IFCC, 
which is certified for its total IgG content. This material 
is known to be stable for at least 10 years for IgG. There-
fore, a similar stability is assumed for this new material. 
In addition, the material, as for any CRM produced by 
our Institute, is included in a yearly stability monitoring 
programme.
Development of ERM-DA483/IFCC
According to the current guidelines, in order for a refer-
ence material to be used as a calibrator, it has to fulfil 
a certain number of criteria: it has to be homogeneous 
between and within the values produced, it must be stable 
during transport and storage and must be commutable 
[10]. Additionally, as important is the possibility to assign 
a property value that is traceable to a stable reference.
ERM-DA483/IFCC was prepared as for previous mate-
rials [19]. From the performed commutability studies it 
was found that the conversion into serum, freeze-drying 
and the addition of preservatives did not interfere with 
the commutability of the material. SSIG plasmapheresis 
material was thus chosen for the development of the CRM, 
ERM-DA483/IFCC [12].
Homogeneity and stability of the CRM
Homogeneity
The determination of the between-vial heterogeneity is 
a key requirement for any CRM aliquoted into units [20]. 
The homogeneity study was performed by measuring 14 
vials, each in triplicate. The standard deviation between 
vial (sbv,rel) and standard deviation within vial (swv,rel) were 
determined by performing an ANOVA of the results. The 
standard deviation between batch (sbv,rel) is less than 1% 
(Table 5), and the material is thus sufficiently homog-
enous for its intended use.
Stability
Analysis of the CRM for PR3  showed that the material 
can be dispatched at temperatures of −70 °C or below, as 
the uncertainty associated with it for a period of 1 week 
was 0.1%, which is negligible with respect to other 
uncertainties.
In regard to the long-term stability of the material, 
no statistical trends were observed at a 95% confidence 
level, neither after 6 nor after 12 months of storage. The 
associated uncertainty for a storage period of 12 months at 
−70 °C was 1.14%. Therefore the material should be stored 
at −70 °C.
Value assignment
For the assignment of a concentration value to the mate-
rial, we followed the value transfer protocol as described 
by Blirup-Jensen et al. [14]. In the chosen approach, a value 
is transferred from a pure protein to the serum protein 
preparation. Based on the slopes plotted from the results 
between the purified PR3 ANCA IgG (pure protein) and the 
CRM (serum protein), the transfer factors for each assay 
are calculated and through them and through knowing 
the concentration of the PR3 ANCA IgG, it is possible to 
calculate the concentration of this protein in the CRM in 
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Figure 3: Examples of results for the commutability study.
In every graph from A–H, absorbance results for combinations of some of the assays used in the study are shown. Results for clinical 
samples are indicated with black squares and results for the selected CRM as empty triangles. The CRM is commutable in all cases even 
though not all curves are linear.
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an SI unit (mg/L). The detailed procedure is published in 
the certification report of the material [12] and the ana-
lytical principles on which the characterisation measure-
ments are based on, are listed by the Joint Committee for 
Traceability of Laboratory Medicine (JCTLM).
Figure 4 shows the average values for the CRM for each 
of the assays. The plot shows both the values in the assay 
scale obtained using the assay calibrator and the values 
after recalibration with the common calibration solutions 
from the purified PR3 IgG ANCA. This graph demonstrates 
that by the use of a common calibrant, results are less 
dispersed.
Uncertainty
For every value property in a CRM, an uncertainty is being 
calculated and reported (Table 5). The assigned combined 
uncertainty is the combination of all relevant uncer-
tainty contributions; it is calculated according to ISO/IEC 
Guide 98-3 [21]. The greatest contribution is coming from 
the characterisation process of the CRM, while another 
important contributor is the characterisation of the puri-
fied PR3 ANCA IgG. Smaller contributors are the homoge-
neity and the long-term stability while a small part of the 
total uncertainty is due to the short-term stability of the 
CRM (Figure 5).
Conclusions
The impact of the lack of standardisation on laboratory 
results for ANCA has already been discussed [22]. A labora-
tory result needs to be accurate and conclusive so as to be 
of value to the requesting clinician ensuring correct diag-
nosis, prognosis and monitoring of the disease. Despite 
the evolution of testing and the automation of techniques 
and of their steps, laboratory results may still vary signifi-
cantly and the assumption that the results are the same 
independently of the assay used is often incorrect.
Hutu et al. showed in a commutability study for MPO 
ANCA IgG that only 10 out the 30 clinical samples tested 
had the same classification amongst the assays used [23]. 
In our study for PR3 ANCA IgG antibodies the results were 
better, 24 out of 30 samples had the same classification. 
Nevertheless, it is worrying that a significant fraction of 
the assay results could lead to different conclusions in 
regard to the patient status if only the assay results would 
be taken into account.
Table 5: Uncertainty budget for the mass concentration of PR3 ANCA IgG in ERM-DA483/IFCC.
CRM code u IgG PR3 ANCA rel
[%]
uchar rel
[%]
ubb rel
[%]
usts rel
[%]
ults rel
[%]
uCRM rel
[%]
Certified value
[mg/L]
UCRM (k = 2)
[mg/L]
ERM-DA483/IFCC 2.75 4.37 0.97 0.09 1.14 5.33 270 29
uIgG PR3 ANCA, Standard uncertainty of the purified protein; uchar, Standard uncertainty of the material characterisation; ubb, Standard uncertainty 
relating to a possible between-unit inhomogeneity; usts, Standard uncertainty of the short-term stability; ults Standard uncertainty of the 
long-term stability; uCRM, Combined standard uncertainty of the certified value; UCRM, Expanded uncertainty of the certified value.
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Figure 4: Comparison of response values for each laboratory 
participating in the study before and after correction with the CRM 
used as calibrant.
With the grey rhombus signs the values as reported by the 
laboratories are shown (in various units). With the black circles, 
those values were corrected using the CRM and are finally reported 
in the same unit (mg/L).
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Figure 5: Graphic representation of the relative contribution of each 
parameter to the total uncertainty.
Uncertainty related to homogeneity (uhom), short- (usts)- and long- 
(ults) term stability, uncertainty related to the characterisation 
process of the CRM (uchar) and of the purified protein (uPR3 ANCA).
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The results of these studies confirm that there is a con-
siderable variability in results from PR3 ANCA IgG testing, 
despite the fact that the different assays performed well in 
terms of precision. We have performed two commutabil-
ity studies in order to assess which PR3 ANCA IgG formats 
are commutable. The chosen format behaved in a manner 
comparable to the majority of typical samples in terms of 
inter-assay properties and dilution behaviour. Its use for 
calibration could reduce between-assay variation [23, 24], 
improve linearity between assay results with respect to 
the reference material and to each other, as demonstrated 
from the commutability data presented in this paper but 
also for the ERM-DA476/IFCC material, which is certified 
for its MPO ANCA IgG content [23], and eventually control 
the variation caused by lot to lot differences of the used 
reagents, as future lots of the same assay would be pre-
pared based on the same CRM [23]. Assay results cannot 
always be harmonised by simple linear corrections, as 
results from some assays have a non-linear relationship 
to the PR3 IgG ANCA concentration and to results from 
other assays. A number of groups has worked on compar-
ing the performance of different ELISAs for ANCA anti-
bodies and have all concluded that despite the sensitivity 
and specificity of the assays available, variation due to 
the biochemical properties of the samples and antibodies 
present, exist [25–27]. These differences were still present 
between some of the assays when an older RM developed 
by the International Union of Immunological Societies 
(IUIS)/Centers for Disease Control and Prevention (CDC) 
was used [27].
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